Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bachem Holding AGBCHMF 96 EV-to-EBIT is 33.13 as of Jul. 20, 2026, which is 11% below its 10-year median of 37.17. GuruFocus rates BCHMF with a GF Score™ of 96/100 and a GF Value™ of $98.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 372 Biotechnology companies, Bachem Holding AG ranks worse than 74.73% on this metric.
Bachem Holding AG (OTCPK:BCHMF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bachem Holding AG's Enterprise Value for the quarter that ended in Dec. 2025 was $4,495.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bachem Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $195.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bachem Holding AG EV-to-EBIT Related Terms
Bachem Holding AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bachem Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's EV-to-EBIT falls into.
Bachem Holding AG's current Enterprise Value is $6,471.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bachem Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $195.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bachem Holding AG (BCHMF) has a EV-to-EBIT of 33.13 as of Jul. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bachem Holding AG and its competitors. This is 11% below median its historical median of 37.17. Over the past decade, Bachem Holding AG's EV-to-EBIT has ranged from 25.14 to 128.17. According to the industry distribution chart, Bachem Holding AG ranks #278 out of 372 companies in the Biotechnology industry, placing it in the top 74.7%.
Is Bachem Holding AG's EV-to-EBIT too high?
Bachem Holding AG's current EV-to-EBIT of 33.13 is 11% below median its 10-year median of 37.17. Over the past 10 years, this metric has ranged from a low of 25.14 to a high of 128.17. The Biotechnology industry median EV-to-EBIT is 13.32. Bachem Holding AG's value of 33.13 is 148.8% above this industry median. Based on the distribution chart, Bachem Holding AG ranks #278 out of 372 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bachem Holding AG has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #278 out of 372 companies for EV-to-EBIT. This places Bachem Holding AG in the lower half of its industry. The industry median EV-to-EBIT is 13.32. Bachem Holding AG's value of 33.13 is 148.8% above this benchmark. Historically, Bachem Holding AG's own EV-to-EBIT has ranged from 25.14 to 128.17 over the past decade. While the company's 10-year median is 37.17 vs. the industry median of 13.32, Bachem Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.32, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bachem Holding AG's current EV-to-EBIT of 33.13 is 148.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bachem Holding AG and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bachem Holding AG's current EV-to-EBIT is 33.13, which is 11% below median its own 10-year median of 37.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.98, compared to a current price of $87.34 — trading 11.8% below its estimated fair value. The current EV-to-EBIT is 33.13, which is 11% below median its 10-year median of 37.17 and 148.8% above the Biotechnology industry median of 13.32. Bachem Holding AG's overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current EV-to-EBIT is 33.13 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 11.8% below its estimated GF Value™ of $98.98.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
EV-to-EBIT: 33.13 (11% below median its 10-year median of 37.17)
GF Value™: $98.98 vs. price of $87.34 (11.8% below fair value)
Industry Position: 148.8% above the Biotechnology median (#278 of 372)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
96GF Score
Get the complete analysis for BCHMF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
